Aberrant Glycogen in Lung Adenocarcinoma Tumorigenesis

Grants and Contracts Details


Diagnosis of non-precision medicine targetable lung cancer represents a bleak future with lower chance of survival and a poor quality of life. For many lung cancer patients, the only treatment options available are traditional multi-agent chemotherapy coupled with surgery and/or radiation. This project will explore the pathogenic roles of glycogen in lung cancer biology and progression and drive the discovery of personalized therapies that can be leveraged for the lung cancer patients that only qualify for conventional chemotherapy.
Effective start/end date11/1/226/30/27


  • University of Florida: $129,312.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.